RxDoctor Payments DataLook up a doctor →

Prashant Koshy, MD

Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1982871695

Payments from drug & device makers

$794,563in general payments, 2019–2025

Across 900 payments — averaging $882.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$669K
  • Amgen$66K
  • Biogen$45K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Corcept Therapeutics$914
  • plus $10K from 54 others
$14,944in research payments, 2019–2025

Across 3 payments — averaging $4981.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$15K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly33$668,957
Amgen(2 entities)73$66,141
Biogen9$45,486
Novo Nordisk134$2,082
Lilly USA, LLC65$1,246
Corcept Therapeutics43$914
Mannkind Corporation52$848
AbbVie46$826
AstraZeneca(2 entities)38$725
Dexcom, Inc.31$668
Abbott31$601
Radius Health, Inc.31$472
Bayer23$414
Sanofi-aventis U.S. LLC24$356
Xeris Pharmaceuticals, Inc.18$344
Boehringer Ingelheim20$326
Recordati_rare_diseases_inc.13$282
Companion Medical, Inc.10$270
Insulet Corporation14$252
Zealand Pharma US, Inc.14$244
IBSA Pharma Inc.14$199
Tandem Diabetes Care, Inc.10$199
Cequr Corporation5$188
Valeritas, Inc.17$187
Amneal Pharmaceuticals LLC10$170
Intuity Medical Inc9$163
Esperion Therapeutics, Inc.8$144
BETA Bionics, Inc.15$127
Merck9$115
Antares Pharma, Inc.6$106
Ascensia Diabetes Care US Inc.2$103
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$99
Neurocrine Biosciences, Inc.3$88
Amarin Pharma, Inc.5$87
Medtronic(3 entities)5$86
Echosens North America, Inc.1$84
Amryt Pharma Holdings Ltd4$80
Avvisto Therapeutics, LLC4$75
Madrigal Pharmaceuticals3$68
Pfizer4$67
Currax Pharmaceuticals LLC4$58
Ascendis Pharma Endocrinology Inc2$57
Curium US LLC2$46
Ultragenyx Pharmaceutical Inc.2$43
Sequel Med Tech, LLC2$40
Azurity Pharmaceuticals, Inc.2$40
Averitas Pharma Inc.2$39
Eisai Inc.2$38
Acella Pharmaceuticals, LLC2$32
Novartis1$29
Kyowa Kirin, Inc.1$24
Coala Life Inc1$19
Halozyme Inc1$18
Novo Nordisk AS2$18
Rhythm Pharmaceuticals, Inc.1$18
Ipsen Biopharmaceuticals, Inc1$17
Tolmar, Inc.1$16
GSK1$16
Astellas Pharma US Inc1$15
Kowa Pharmaceuticals America, Inc.1$14

How this compares

$794,563 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024
$335,951
Medicare patients
631
Services billed
8,470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →